Published in Mol Neurobiol on October 01, 2005
Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci (2008) 1.58
Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology (2008) 1.32
Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology (2008) 1.28
Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem (2009) 1.28
Progress in neuroprotective strategies for preventing epilepsy. Prog Neurobiol (2007) 1.24
Bipolar disorder: from genes to behavior pathways. J Clin Invest (2009) 1.24
Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study. Psychopharmacology (Berl) (2007) 1.17
Effects of the Chinese traditional prescription Xiaoyaosan decoction on chronic immobilization stress-induced changes in behavior and brain BDNF, TrkB, and NT-3 in rats. Cell Mol Neurobiol (2007) 1.14
In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol Psychiatry (2007) 1.10
Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. J Affect Disord (2009) 1.08
Are Bipolar Disorder and Schizophrenia Neuroanatomically Distinct? An Anatomical Likelihood Meta-analysis. Front Hum Neurosci (2010) 1.08
Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway. Br J Pharmacol (2006) 1.07
Cell atrophy and loss in depression: reversal by antidepressant treatment. Curr Opin Cell Biol (2011) 1.01
Chronic carbamazepine administration reduces N-methyl-D-aspartate receptor-initiated signaling via arachidonic acid in rat brain. Biol Psychiatry (2007) 0.96
Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex. Neurochem Res (2008) 0.92
DISC1 Pathway in Brain Development: Exploring Therapeutic Targets for Major Psychiatric Disorders. Front Psychiatry (2012) 0.90
DHA deficiency and prefrontal cortex neuropathology in recurrent affective disorders. J Nutr (2010) 0.89
Lithium and GSK3-β promoter gene variants influence white matter microstructure in bipolar disorder. Neuropsychopharmacology (2012) 0.88
Molecular pharmacology in a simple model system: implicating MAP kinase and phosphoinositide signalling in bipolar disorder. Semin Cell Dev Biol (2010) 0.87
Posterior cerebellar vermal deficits in bipolar disorder. J Affect Disord (2013) 0.87
Subcortical volumetric abnormalities in bipolar disorder. Mol Psychiatry (2016) 0.86
Glucocorticoid receptors modulate mitochondrial function: A novel mechanism for neuroprotection. Commun Integr Biol (2009) 0.86
Expression profiling in neuropsychiatric disorders: emphasis on glutamate receptors in bipolar disorder. Pharmacol Biochem Behav (2011) 0.85
Peony glycosides protect against corticosterone-induced neurotoxicity in PC12 cells. Cell Mol Neurobiol (2009) 0.83
The effectiveness of anticonvulsants in psychiatric disorders. Dialogues Clin Neurosci (2008) 0.82
Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer. Front Pharmacol (2015) 0.81
Trehalose induced antidepressant-like effects and autophagy enhancement in mice. Psychopharmacology (Berl) (2013) 0.81
Protective effects of piperine against corticosterone-induced neurotoxicity in PC12 cells. Cell Mol Neurobiol (2011) 0.80
Acute and chronic effects of lithium on BDNF and GDNF mRNA and protein levels in rat primary neuronal, astroglial and neuroastroglia cultures. Iran J Basic Med Sci (2015) 0.77
Lithium prevents aberrant NMDA-induced F-actin reorganization in neurons. Neuroreport (2014) 0.76
A Pilot Study for Discovering Candidate Genes of Chromosome 18q21 in Methamphetamine Abusers: Case-control Association Study. Clin Psychopharmacol Neurosci (2014) 0.76
Early intervention in bipolar disorder, part II: therapeutics. Early Interv Psychiatry (2008) 0.76
Preclinical Evidences for an Antimanic Effect of Carvedilol. Neural Plast (2015) 0.75
Heritability and Familiality of Temperament and Character Dimensions in Korean Families with Schizophrenic Linkage Disequilibrium. Clin Psychopharmacol Neurosci (2016) 0.75
Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions. Int J Mol Sci (2017) 0.75
Decreased levels of canonical transient receptor potential channel 3 protein in the rat cerebral cortex after chronic treatment with lithium or valproate. Res Pharm Sci (2016) 0.75
A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts. Neuropsychiatr Dis Treat (2016) 0.75
Brain Structural Effects of Psychopharmacological Treatment in Bipolar Disorder. Curr Neuropharmacol (2015) 0.75
The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry (2003) 21.70
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 4.90
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci (2004) 2.17
Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry (2006) 2.09
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE (2004) 2.04
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 1.90
A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 1.83
AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 1.79
Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology (2008) 1.79
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord (2007) 1.74
An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry (2004) 1.71
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans. Biol Psychiatry (2010) 1.70
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry (2005) 1.65
Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65
The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
The Wnt signaling pathway in bipolar disorder. Neuroscientist (2002) 1.53
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry (2009) 1.51
Critical role of promoter IV-driven BDNF transcription in GABAergic transmission and synaptic plasticity in the prefrontal cortex. Proc Natl Acad Sci U S A (2009) 1.46
Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci (2004) 1.45
Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology (2007) 1.42
Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology (2007) 1.41
Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology (2008) 1.41
In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology (2004) 1.41
Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Med (2010) 1.41
CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog Neurobiol (2012) 1.40
Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry (2007) 1.40
Molecular effects of lithium. Mol Interv (2004) 1.39
Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A (2009) 1.38
A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry (2009) 1.33
Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study. Biol Psychiatry (2010) 1.32
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry (2004) 1.29
Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology (2008) 1.29
The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents. Biol Psychiatry (2009) 1.29
A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol (2009) 1.28
Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology (2010) 1.25
BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. Proc Natl Acad Sci U S A (2008) 1.25
Endophenotypes in bipolar disorder. Am J Med Genet (2002) 1.25
The mouse forced swim test. J Vis Exp (2012) 1.24
Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology (2006) 1.24
Bipolar disorder: from genes to behavior pathways. J Clin Invest (2009) 1.24
Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions. Metabolomics (2010) 1.23
Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry (2006) 1.23
Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets (2006) 1.23
Suppression of adult neurogenesis leads to an increased hypothalamo-pituitary-adrenal axis response. Neuroreport (2009) 1.23
Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry (2013) 1.21
The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci (2008) 1.19
Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 1.19
Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol (2006) 1.16
Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication. Neuroimage (2009) 1.16
Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. Neuropharmacology (2007) 1.16
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist (2009) 1.13
Post-mortem interval effects on the phosphorylation of signaling proteins. Neuropsychopharmacology (2003) 1.13
Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry (2006) 1.13
Regional cerebral glucose metabolic abnormalities in bipolar II depression. Biol Psychiatry (2006) 1.13
Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Biol Psychiatry (2006) 1.12
G protein-coupled receptors in major psychiatric disorders. Biochim Biophys Acta (2006) 1.12
The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. Neurosci Biobehav Rev (2007) 1.12
Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci (2003) 1.11
A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci U S A (2010) 1.11
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol (2012) 1.11
Generation and behavioral characterization of beta-catenin forebrain-specific conditional knock-out mice. Behav Brain Res (2008) 1.10
The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci (2005) 1.10
In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol Psychiatry (2007) 1.10
MicroRNAs in mental health: from biological underpinnings to potential therapies. Neuromolecular Med (2009) 1.09
Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. J Affect Disord (2009) 1.08
Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull (2002) 1.07
Glucocorticoids orchestrate divergent effects on mood through adult neurogenesis. J Neurosci (2013) 1.07
Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology (2008) 1.07
Signal transduction and genes-to-behaviors pathways in psychiatric diseases. Sci STKE (2003) 1.06
The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers. Curr Opin Psychiatry (2006) 1.04
Mood-stabilizing drugs: mechanisms of action. Trends Neurosci (2012) 1.03
Performance on a virtual reality spatial memory navigation task in depressed patients. Am J Psychiatry (2007) 1.03
Activity-dependent brain-derived neurotrophic factor expression regulates cortistatin-interneurons and sleep behavior. Mol Brain (2011) 1.03
The tail suspension test. J Vis Exp (2012) 1.02
Increased anxiety-like behaviors and mitochondrial dysfunction in mice with targeted mutation of the Bcl-2 gene: further support for the involvement of mitochondrial function in anxiety disorders. Behav Brain Res (2005) 1.02
Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway. CNS Neurol Disord Drug Targets (2007) 1.01
Getting balance: drugs for bipolar disorder share target. Nat Med (2002) 1.00